Nimodipina Labesfal (Nimodipine)

Nimodipine, the active ingredient in Nimodipina Labesfal, is a calcium channel blocker presented as an oral formulation for oral use. It is employed to prevent cerebral vasospasm following subarachnoid hemorrhage in adult patients. GNH USA supplies Nimodipina Labesfal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nimodipine acts on the cerebral vasculature to reduce the risk of vasospasm after bleeding into the subarachnoid space. - Subarachnoid hemorrhage: helps prevent delayed cerebral vasospasm and associated ischemic complications. - Neurosurgical postoperative care: supports vascular stability in patients at risk of vasospasm after aneurysm clipping or coiling. - Neurocritical care: contributes to overall neuroprotection strategies in intensive‑care settings.

Nimodipine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Hypotension: reduction in blood pressure, especially when standing. - Nausea or vomiting: gastrointestinal discomfort that may resolve with continued therapy. - Dizziness or light‑headedness: related to blood pressure changes. - Flushing: warm sensation and reddening of the skin.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Myocardial infarction: rare cardiac events in susceptible individuals. - Hepatic dysfunction: abnormal liver enzymes or hepatitis. - Severe allergic reactions: rash, itching, swelling, or anaphylaxis. - Thrombocytopenia: low platelet count with potential bleeding risk.

Before initiating Nimodipina Labesfal, clinicians should consider several safety measures. - Blood pressure monitoring: check for hypotension, especially after the first dose. - Hepatic function: assess liver enzymes in patients with known liver disease. - Concomitant vasodilators: use cautiously with other agents that lower blood pressure. - Abrupt discontinuation: avoid sudden stop; taper if long‑term therapy is required. - Pregnancy and lactation: safety not established; weigh risks and benefits. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Nimodipine can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other calcium channel blockers: additive vasodilatory effect may cause severe hypotension. - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase nimodipine plasma levels, raising toxicity risk. - Strong hypotensive agents (e.g., nitroglycerin): may lead to dangerous blood pressure drops.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce nimodipine exposure, potentially diminishing efficacy. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt vasodilatory response. - Beta‑blockers: combined effect on heart rate and blood pressure requires observation.